---
layout: post
title: "中关村：氨酚曲马多片一致性评价申报获受理"
date: 2022-03-24 18:10:47 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.000931" data-code="000931|0|2" data-code2="000931|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.000931&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 000931_0" data-code="K 000931|0|2" data-code2="K 000931|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>中关村(000931)3月24日晚间公告，全资子公司北京中关村四环医药开发有限责任公司之控股子公司多多药业收到国家药监局下发的氨酚曲马多片一致性评价《受理通知书》。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203242321988370>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)